Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 33
Filter
1.
BIOpreparations ; Prevention, Diagnosis, Treatment. 22(4):446-459, 2022.
Article in Russian | EMBASE | ID: covidwho-2269580

ABSTRACT

The COVID-19 mortality is associated with an increase in interleukin-6 (IL-6) levels. Levilimab is an anti-IL-6 receptor antibody with proven clinical efficacy in patients with severe COVID-19. The aim of the study was to assess the association of COVID-19 severity and levilimab effectiveness with IL-6 levels and to explore the potential for using levilimab in other conditions accompanied by cytokine release syndrome. Material(s) and Method(s): the subgroup analysis was based on the data of COVID patients with known baseline IL-6 levels from the CORONA clinical study. Subgroups were formed according to baseline IL-6 levels: <=5 pg/mL (normal) and >5 pg/mL (elevated). The subgroup analysis included descriptive statistics of the patients and time courses of their clinical and laboratory findings (at screening, on the day of investigational product administration, and further until day 14). In order to compare the percentages of patients who had required rescue therapy, the authors used Fisher's exact test. Result(s): the subgroup analysis included 91 patients (47 from the levilimab group and 44 from the placebo group). At baseline, the authors observed elevated levels of IL-6 in 31/47 (66%) subjects in the levilimab group and 29/44 (48.4%) subjects in the placebo group. The subjects with elevated IL-6 demonstrated more pronounced clinical signs of pneumonia and abnormalities in inflammatory markers. Elevated baseline IL-6 levels were associated with the need for rescue therapy (OR=3.714;95% CI: 1.317-9.747;p=0.0183);this association was stronger in the placebo group (OR=8.889;95% CI: 2.098-33.31;p=0.0036). Also, the placebo group showed long-term abnormalities in the clinical and laboratory findings. Conclusion(s): IL-6 is one of the key elements in the pathogenesis of cytokine release syndrome related to COVID-19 and other conditions. Elevated IL-6 levels are associated with the severity of COVID-19. Inhibition of IL-6 receptors by levilimab leads to clinical improvement in patients with severe COVID-19, suggesting the effectiveness of levilimab in pathogenesis-oriented therapy for cytokine release syndrome of other aetiologies.Copyright © 2023 Safety and Risk of Pharmacotherapy. All rights reserved.

2.
Chinese Journal of Radiological Medicine and Protection ; 40(4):259-263, 2020.
Article in Chinese | EMBASE | ID: covidwho-2286054

ABSTRACT

X-ray imaging is an important method for the diagnosis of corona virus disease(COVID-19), but there is a risk of nosocomial infection during X-ray imaging and diagnosis. By analyzing the process of X-ray imaging & diagnosis and the possible exposure factors in hospital, Jiangsu province took the lead in issuing the guideline for the nosocomial infection prevention and control of COVID-19 during X-ray imaging and diagnosis. This guideline clarifies the basic requirements for controlling infections during X-ray imaging and diagnosis, the specific measures for staff protection, disinfection of personnel and sites, and the protection and disinfection of subjects, which is instructive for on-site work. It is worth noting that while focusing on controlling infections, the principle of optimal protection for medical exposure cannot be ignored.Copyright © 2020 by the Chinese Medical Association.

3.
American Biology Teacher ; 85(1):23-32, 2023.
Article in English | Scopus | ID: covidwho-2255134

ABSTRACT

The use of virtual reality (VR) as a medium for education can contribute to the learning efficiency of students. This study aimed to assess the effectiveness of VR application in advanced biology courses, specifically in enhancing the comprehension and understanding of high school students toward the topic of human organs and other related systems. Four high school teachers and 138 high school students selected from three separate classes participated in this study. To determine the impact of VR education from both teachers' and students' perspectives, learning satisfaction and the effectiveness of instructional material were assessed with questionnaires. We found that from teachers' perspective, VR was an efficient teaching tool that enhanced students' attention and contributed to the improvement of learning outcomes. From the students' perspective, they were willing to use VR instructional material and were satisfied with this learning method. Applying VR technology in the classroom should be encouraged. However, some students identified dizziness as a concern when VR glasses were used for longer periods of time. Therefore, we suggest that VR glasses be limited to 30 minutes of use at a time. © 2023 National Association of Biology Teachers, Inc. All rights reserved.

4.
Probl Endokrinol (Mosk) ; 68(6): 89-109, 2023 Jan 24.
Article in Russian | MEDLINE | ID: covidwho-2250285

ABSTRACT

BACKGROUND: There is enough evidence of the negative impact of excess weight on the formation and progression of res piratory pathology. Given the continuing SARS-CoV-2 pandemic, it is relevant to determine the relationship between body mass index (BMI) and the clinical features of the novel coronavirus infection (NCI). AIM: To study the effect of BMI on the course of the acute SARS-COV-2 infection and the post-covid period. MATERIALS AND METHODS: AKTIV and AKTIV 2 are multicenter non-interventional real-world registers. The АКТИВ registry (n=6396) includes non-overlapping outpatient and inpatient arms with 6 visits in each. The АКТИВ 2 registry (n=2968) collected  the  data  of  hospitalized  patients  and  included  3  visits.  All  subjects  were  divided  into  3  groups:  not  overweight  (n=2139), overweight (n=2931) and obese (n=2666). RESULTS: A higher BMI was significantly associated with a more severe course of the infection in the form of acute kidney injury (p=0.018), cytokine storm (p<0.001), serum C-reactive protein over 100 mg/l (p<0.001), and the need for targeted therapy (p<0.001) in the hospitalized patients. Obesity increased the odds of myocarditis by 1,84 times (95% confidence interval [CI]: 1,13-3,00) and the need for anticytokine therapy by 1,7 times (95% CI: 1,30-2,30).The  patients  with  the  1st  and  2nd  degree  obesity,  undergoing  the  inpatient  treatment,  tended  to  have  a  higher  probability  of  a  mortality  rate.  While  in  case  of  morbid  obesity  patients  this  tendency  is  the  most  significant  (odds  ratio  -  1,78; 95% CI: 1,13-2,70). At the same time, the patients whose chronical diseases first appeared after the convalescence period, and those who had certain complaints missing before SARS-CoV-2 infection, more often had BMI of more than 30 kg/m2 (p<0,001).Additionally, the odds of death increased by 2,23 times (95% CI: 1,05-4,72) within 3 months after recovery in obese people over the age of 60 yearsCONCLUSION.  Overweight  and/or  obesity  is  a  significant  risk  factor  for severe  course  of  the  new  coronavirus  infection  and  the associated cardiovascular and kidney damage Overweight people and patients with the 1st and 2nd degree obesity tend to have a high risk of death of SARS-CoV-2 infection in both acute and post-covid periods. On top of that, in case of morbid obesity patients this tendency is statistically significant. Normalization of body weight is a strategic objective of modern medicine and can contribute to prevention of respiratory conditions, severe course and complications of the new coronavirus infection.


Subject(s)
COVID-19 , Humans , Middle Aged , SARS-CoV-2 , Body Mass Index , Patient Discharge , Overweight , Hospitals , Obesity
5.
Kardiologiia ; 62(12): 23-29, 2022 Dec 31.
Article in Russian, English | MEDLINE | ID: covidwho-2248180

ABSTRACT

Aim      To evaluate functional changes in the heart in the long-term following COVID-19 in patients with chronic heart failure (CHF).Material and methods  Case reports of 54 patients aged 69.1±9.7 years who had COVID-19 from January 2021 through January 2022 and had been previously diagnosed with NYHA functional class II-III CHF were studied. Two comparison groups were isolated: HF with LV EF >50 % (n=39) and <50 % (n=15). Echocardiography was used to evaluate changes in LV EF and pulmonary artery systolic pressure (PASP) 5-6 months following COVID-19.Results In all CHF patients after COVID-19 at 5.8 months on average, LV EF decreased (median difference, 2.5 %; 95 % confidence interval (CI): 6.99×10-5- 4.99) and PASP increased (median difference, 8 mm Hg; 95 % CI: 4.5-12.9). In the HF group with LV EF <50 %, the decrease in EF was greater than in the group with LV EF >50 % (6.9 and 0.7 %, respectively; p=0.037); furthermore, the CHF phenotype did not influence the change in PASP (p=0.4). The one-factor regression analysis showed that the dynamics of LV EF decrease was significantly influenced by the baseline decrease in LV EF, whereas the change in PASP was influenced by the dynamics of LV EF decrease, presence of dyslipidemia, and statin treatment. Furthermore, the multifactorial analysis showed that prognostically significant factors for long-term changes in LV EF following COVID-19 were male gender (odds ratio (OR), 5.92; 95 % CI: 1.31-26.75; p=0.014), LV EF at baseline <50 % (OR, 0.88; 95 % CI: 0.8-0.96; p<0.001); changes in PASP depended on the presence of dyslipidemia (OR, 0.08; 95 % CI: 0.01-0.84; p=0.018).Conclusion      This study showed that COVID-19 in the long term can influence the course of CHF; in this process, HF patients with EF <50 % have progression of systolic dysfunction and PASP, whereas patients with EF >50 % have an isolated increase in PASP.


Subject(s)
COVID-19 , Heart Failure , Male , Female , Humans , Stroke Volume , COVID-19/complications , Heart Failure/diagnosis , Heart Failure/epidemiology , Chronic Disease , Ventricular Function, Left
6.
BIOpreparations. Prevention, Diagnosis, Treatment ; 22(4):446-459, 2022.
Article in Russian | EMBASE | ID: covidwho-2242841

ABSTRACT

The COVID-19 mortality is associated with an increase in interleukin-6 (IL-6) levels. Levilimab is an anti–IL-6 receptor antibody with proven clinical efficacy in patients with severe COVID-19. The aim of the study was to assess the association of COVID-19 severity and levilimab effectiveness with IL-6 levels and to explore the potential for using levilimab in other conditions accompanied by cytokine release syndrome. Materials and methods: the subgroup analysis was based on the data of COVID patients with known baseline IL-6 levels from the CORONA clinical study. Subgroups were formed according to baseline IL-6 levels: ≤5 pg/mL (normal) and >5 pg/mL (elevated). The subgroup analysis included descriptive statistics of the patients and time courses of their clinical and laboratory findings (at screening, on the day of investigational product administration, and further until day 14). In order to compare the percentages of patients who had required rescue therapy, the authors used Fisher's exact test. Results: the subgroup analysis included 91 patients (47 from the levilimab group and 44 from the placebo group). At baseline, the authors observed elevated levels of IL-6 in 31/47 (66%) subjects in the levilimab group and 29/44 (48.4%) subjects in the placebo group. The subjects with elevated IL-6 demonstrated more pronounced clinical signs of pneumonia and abnormalities in inflammatory markers. Elevated baseline IL-6 levels were associated with the need for rescue therapy (OR=3.714;95% CI: 1.317–9.747;p=0.0183);this association was stronger in the placebo group (OR=8.889;95% CI: 2.098–33.31;p=0.0036). Also, the placebo group showed long-term abnormalities in the clinical and laboratory findings. Conclusions: IL-6 is one of the key elements in the pathogenesis of cytokine release syndrome related to COVID-19 and other conditions. Elevated IL-6 levels are associated with the severity of COVID-19. Inhibition of IL-6 receptors by levilimab leads to clinical improvement in patients with severe COVID-19, suggesting the effectiveness of levilimab in pathogenesis-oriented therapy for cytokine release syndrome of other aetiologies.

7.
Open Forum Infectious Diseases ; 9(Supplement 2):S485-S486, 2022.
Article in English | EMBASE | ID: covidwho-2189790

ABSTRACT

Background. Corticosteroids confer a survival benefit in hospitalized COVID-19 patients requiring oxygen, but optimal treatment duration remains uncertain. The goal of this meta-analysis is to determine the optimal duration of corticosteroids in the treatment of severe COVID-19. (Figure Presented) The greatest survival benefit was observed for the treatment duration of up to 6 days (A). No survival benefit was observed beyond 7 days of treatment (B). Methods. Electronic databases (MEDLINE, Scopus, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, the World Health Organization Global Literature on Coronavirus Disease, CoronaCentral, and Web of Science) and trial registries were searched to March 9, 2022, for randomized controlled trials and observational cohort studies reporting corticosteroid versus no corticosteroid treatment in hospitalized COVID-19 patients. Risk of bias was assessed using the Cochrane Risk of Bias tool (randomized controlled trials) or the Newcastle-Ottawa Scale (observational studies). We estimated the effect of corticosteroids on mortality by random-effects meta-analyses using the generic inverse variance method. Subgroup analyses and meta-analyses were conducted to assess the optimal duration of corticosteroid treatment. Results. We identified 28 eligible studies consisting of 13,404 hospitalized COVID-19 patients. Median age was 62 years (interquartile range: 59 - 67), and 65% weremale. Eight randomized controlled trials and 20 observational studieswere included in the meta-analysis of mortality, which suggested a protective association with corticosteroid therapy (risk ratio, 0.75;95% CI: 0.64;0.87). Pooled analysis of 19 studies showed the greatest survival benefit for a treatment duration up to 6 days (risk ratio, 0.54;95% CI, 0.39;0.74). Survival benefit was 0.68 (95% CI, 0.57;0.82) up to 7 days, and no survival benefit was observed beyond 7 days of treatment (risk ratio, 0.71;95% C: 0.51;1.01). Conclusion. In this meta-analysis, the optimal duration of corticosteroid treatment for hospitalized COVID-19 patients was up to 6 days, with no additional survival benefit with > 7 days of treatment. Future analyses should stratify survival benefit by baseline disease severity to see if subgroups of patients derive greater benefit from longer courses of steroids.

8.
Extreme Medicine ; - (2):50-57, 2022.
Article in English | Scopus | ID: covidwho-2146635

ABSTRACT

It is important to control the levels of specific IgG against SARS-CoV-2 to ensure the timely monitoring of immunity in patients with COVID-19. Yet it is unclear what antibody levels protect against new infection and how long the protection is maintained. The study was aimed to assess the dynamic changes in the levels of IgG against SARS-CoV-2 by the two-year controlled observation. Healthy individuals (n = 70), COVID-19 survivors (n = 42), and people vaccinated with Sputnik V (n = 43) were enrolled. They were followed-up from April 2020 to April 2022. Serum IgG levels were defined (n = 312) using immunochip and the commercially available test system. Significance of differences was estimated using the Mann–Whitney U test for р ≤ 0.05. IgG levels in the disease survivors (median 97.1;95% CI: 80–162 BAU/mL) and vaccinated individuals (103.1;78–139 BAU/mL) were significantly higher than in healthy people (4.3;4.1–4.5 BAU/mL). Intensity of immune response significantly increased after vaccination of the disease survivors (up to 1023;657–1191 BAU/mL) or administration of booster dose to vaccinated individuals (413;213–545 BAU/mL). In elderly convalescents (60+), IgG levels were significantly higher, and in vaccinated people these were significantly lower, than in people under the age of 60. IgG levels decreased faster in vaccinated individuals (after 3–4 months), than in the disease survivors, and stabilized at <100 BAU/mL in 60% of subjects within 5–9 months. Thus, intensity and duration of immune response in COVID-19 survivors and vaccinated people vary significantly depending on age, observation period, and additional vaccinations/revaccinations. Three cases of infection after full vaccination were reported over the entire follow-up period, including infection in a patient having a history of the disease and subsequent vaccination. © 2022 Federal Medical Biological Agency Publishing Group. All Rights Reserved.

9.
Klinicheskaya Onkogematologiya/Clinical Oncohematology ; 15(3):282-288, 2022.
Article in Russian | Scopus | ID: covidwho-2145973

ABSTRACT

Background. The treatment of elderly patients with acute myeloid leukemias (AML) is one of the most formidable challenges in oncohematology. Hypomethylating drugs combined with venetoclax show relatively high efficacy and lower toxicity in elderly AML patients. Aim. To retrospectively analyze the efficacy and tolerability of the combined azacitidine/venetoclax therapy in AML primary patients of older age as well as to determine a spectrum of issues related to the implementation of this regimen in real-world clinical practice. Materials & Methods. The retrospective analysis enrolled a cohort of patients followed-up at the Botkin City Clinical Hospital (n = 35). The median age was 73 years (range 60-90 years), 57 % of patients were over 70 years of age. The median follow-up duration was 5.2 months (range 1.6-42.6 months). By the time of final analysis 15 patients were still receiving the therapy. The median of overall survival was 11.1 months (95% confidence interval [95% CI] 8.1-14.1 months). The causes of death in 20 patients were AML progression (n = 3), non-COVID-19 infectious complications (n = 3), and COVID-19 (n = 10). In 4 patients the cause of death remained unidentified. Results. Complete remission (CR) was documented in 17 (48.5 %) patients;CR with incomplete hematologic recovery was identified in 9 (26 %) patients. The median time before achieving remission was 67 days (range 27-120 days). In 96 % of patients CR was achieved after 3 azacitidine/venetoclax cycles. The mean CR duration was 9.2 months (95% CI 5.7-12.6 months);the median time before loss of response was 19 months. Relapses were diagnosed in 5 patients. Neutropenia > grade 3 was identified in patients who achieved remission on subsequent therapy cycles in 100 % of cases (n = 26), anemia > grade 2 was reported in 9 (34 %) patients, and thrombocytopenia > grade 3 was detected in 13 (50 %) patients. Despite frequent neutropenia, patients with remission did not show any severe infectious complications. Conclusion. The combined azacitidine/venetoclax therapy in elderly patients yields remission in more than 70 % of cases and is not marked by any severe infectious complications, despite developing neutropenia. Due to its ease of administration and low toxicity, this regimen can be performed in outpatient units. © 2022 Practical Medicine Publishing House. All rights reserved.

10.
12th International Conference on CYBER Technology in Automation, Control, and Intelligent Systems, CYBER 2022 ; : 474-479, 2022.
Article in English | Scopus | ID: covidwho-2120884

ABSTRACT

Parkinson's disease(PD) is a progressive neu-rodegenerative disease defined by clinical syndrome including bradykinesia, tremor and postural instability. The PD-related disability and impairment are usually monitored by clinicals using the MDS-UPDRS scale. However, due to COVID-19, it became much harder for the patients to reach hospitals and obtain necessary assessment and treatment. Nowadays, 2D videos are easily accessible and can be a promising so-lution for on-site and remote diagnosis of movement disorder. Inspired by the frequency-based video processing mechanism of human visual system, we propose a video-based SlowFast GCN network to quantify the gait disorder. The model consists of two parts: the fast pathway and the slow pathway. The former detects characteristics such as tremor and bilateral asymmetry, while the latter extracts characteristics such as bradykinesia and freezing of gait. Furthermore, in order to investigate the influence of age on the model performance, an aged control group and a young control group were set up for verification. The proposed model was evaluated on a video dataset collected from 68 participants. We achieved a balanced accuracy of 87.5% and precision of 87.9%, which outperformed existing competing methods. When replacing the young healthy controls with the same number of older controls, the balanced accuracy and precision were decreased by 10.4% and 9.7%, which indicates that age has a significant effect on the model perfomance. © 2022 IEEE.

11.
Bull Exp Biol Med ; 173(6): 734-739, 2022 Oct.
Article in English | MEDLINE | ID: covidwho-2094660

ABSTRACT

IgM and IgG antibodies to the SARS-CoV-2 virus are detected in subjects who have recovered from COVID-19; IgM antibodies persist in a 1/3 of infected subjects up to 12 months from the moment of the disease, while IgG antibodies are present in the vast majority of cases (97%; medium and high levels antibodies were registered in 85% of cases). By the 12th month, 40% of those who recovered still have a very high level of IgG antibodies to the S-protein (>500 BAU/ml). In the feces, urine, and blood serum of patients with long-term persistent IgM antibodies, no coronavirus antigens were detected. After vaccination with the Gam-COVID-Vac vaccine, IgG antibodies to the S-protein are detected in 100% of cases and remain at a high level for 4 months, by the 5-6th month, the level of antibodies decreases. During revaccination, the level of IgG antibodies to S-protein reaches high values earlier than during primary vaccination, and remains high for 4 months (observation period). The blood sera of recovered and vaccinated patients have a high virus-neutralizing activity (at least 1:80), while its level is somewhat higher in recovered patients.


Subject(s)
Antibodies, Viral , COVID-19 , Humans , Immunization, Secondary , COVID-19/prevention & control , SARS-CoV-2 , Vaccination , Immunoglobulin M , Immunoglobulin G
12.
Her Russ Acad Sci ; 92(4): 511-519, 2022.
Article in English | MEDLINE | ID: covidwho-2078754

ABSTRACT

The development of electronic services to help doctors in the diagnosis and treatment of COVID-19 is discussed. The existing systems for such purposes are analyzed, and requirements for them are formulated. The architecture of an intelligent medical decision support system and the basic principles of its development using an ontology-oriented approach are given. The unique capabilities of the system are shown, and its information and software components are described.

13.
Gastroenterology ; 162(7):S-43, 2022.
Article in English | EMBASE | ID: covidwho-1967237

ABSTRACT

Background and Aims: Reliance on in-visit, opt-in screening for colorectal cancer (CRC) may be an obstacle to screening, especially during the COVID-19 pandemic and among low income and vulnerable populations. We aim to describe and evaluate the effectiveness of a CRC screening outreach campaign in a safety-net health system testing opt-out and opt-in text message outreach followed by mailed fecal immunochemical test (FIT) kits. Methods: From November 2020 to April 2021, the outreach campaign targeted patients ages 50-75 from 11 primary care clinics within the San Francisco Health Network who had previously completed a FIT test and were overdue for CRC screening. Patients were assigned to receive a language-concordant, pre-alert text message notifying that they would be mailed a FIT kit 1) unless they opted out of receiving a kit or 2) if they opted in to receiving a kit. The primary outcome was screening participation at 3 months after outreach. Results: A total of 371 patients were assigned to receive opt-out text messages and 522 received opt-in text messages. FIT kits were mailed to 96.5% (n = 358) of the opt-out group and 19.3% (n = 101) of the opt-in group. Screening uptake at 3 months was significantly higher in the optout group than in the opt-in group (58.8% vs. 18.0%, P < 0.001;difference = 40.8%, 95% confidence interval 34.8%-46.8%). Black/African American patients had lower screening rates (33.3% in opt-out group and 9.4% in opt-in group) compared to Hispanic/Latino (53.3% in opt-out group and 26.7% in opt-in group) and Asian (66.7% in opt-out group and 26.7% in opt-in group) patients. Conclusions: During the COVID-19 pandemic, optout text messaging followed by mailed FIT kits improved population-level CRC screening rates in a safety-net health system. Tailored initiatives are needed to address low screening rates for Black/African American patients.

14.
Vestn Oftalmol ; 138(3): 41-45, 2022.
Article in Russian | MEDLINE | ID: covidwho-1934754

ABSTRACT

PURPOSE: To evaluate the severity of hemodynamic changes in the ocular vessels of patients recovered from COVID-19. MATERIAL AND METHODS: The study included 44 patients (88 eyes) aged 28-60 years, among them 24 (54.5%) women and 20 (45.4%) men, with SARS-CoV-2 infection confirmed by PCR no more than 2 months prior to enrollment and with no ophthalmological complaints within 2 months before the disease, as well as 20 healthy volunteers (40 eyes). At the time of the study all patients had a negative PCR result for SARS-CoV-2. The patients were divided into 2 groups. The first group comprised 24 patients who did not take any anticoagulants during the treatment. The second group consisted of 20 patients who received anticoagulants (Rivaroxaban (Xarelto)) at a dosage of 10 mg per day for 1-1.5 months. The maximum systolic (Vs), end-diastolic (Vd) blood flow velocity, as well as resistance index (RI) in the ophthalmic artery (OA), central retinal artery (CRA) and short posterior ciliary arteries (SPCA) were measured in all study patients with the ultrasound imaging system VOLUSON E8 Expert («Kretz¼, USA). Additionally, the flowmetry method was used to assess the volumetric ocular blood flow (VOBF) on Ocular Blood Flow Analyzer system («Paradigm Medical Industries, Inc.¼, USA). RESULTS: In the first group, a decrease in Vs and Vd was noted amid a significant increase of RI in CRA and SPCA, as well as an increase of RI in OA compared with the age-normal values (p<0.05). In the second group, a decrease in Vs and Vd was noted amid a significant increase of RI in CRA, as well as a decrease in Vs in SPCA and an increase of RI in OA relative to the age-normal values (p<0.05). A decrease in VOBF was noted in the first group in comparison to the second group and the age norm (p<0.05). CONCLUSION: Blood flow velocity parameters in the ocular vessels are reduced in patients recovered from COVID-19 compared to the age-normal values. There was a significant decrease in volumetric ocular blood flow parameters in COVID-19 patients who did not take any anticoagulants compared to the age-normal values. Anticoagulants intake has a positive impact on hemodynamic characteristics in the ocular vessels and volumetric ocular blood flow in patients with COVID-19.


Subject(s)
COVID-19 , Retinal Artery , Anticoagulants , Blood Flow Velocity/physiology , Female , Hemodynamics , Humans , Male , Ophthalmic Artery/diagnostic imaging , Ophthalmic Artery/physiology , Regional Blood Flow/physiology , Retinal Artery/diagnostic imaging , SARS-CoV-2 , Ultrasonography, Doppler, Color
15.
Izvestiya Vysshikh Uchebnykh Zavedenii, Seriya Teknologiya Tekstil'noi Promyshlennosti ; - (5):94-101, 2021.
Article in Russian | Scopus | ID: covidwho-1912780

ABSTRACT

The World Health Organization has declared the coronavirus an emergency of international importance. In this regard, non-woven materials (NM) are recommended to be actively introduced and used to stop the spread of coronavirus in products for various purposes, including medical devices. Synthetic polyester fillers in pillows, blankets, mattresses, insulation in clothes and buildings are nonbiological non-cellular structure. It does not spread bacteria, which, in turn, like living organisms, microorganisms, can be a medium for viral spread. The fibers used in the production of Hollofiber® materials have a hygroscopicity of less than 1%, they do not have a protein component or a plant cell, which can be a nutrient medium for microorganisms and, accordingly, viruses spread through them. However, the issues of viral transfer and virulence remain relevant and problematic. One effective solution is radiation sterilization. The problem is that not all nonwoven materials (NM) are able to withstand exposure to radiation sterilization. In connection with this object of research, a high-tech NM of domestic production was selected. Thus, the study of the effect of radiation sterilization on Hollofiber® material is an urgent task. As a result of studying Hollofayber® NM after radiation in the dose range from 20-60 kGy, there were no significant changes in consumer characteristics. Thus, NM Hollofayber® PROFI, article P 35191, Hollofayber® SOFT, article P 5197, Plollofayber® SOFT, article P 5200 are recommended for the manufacture of medical devices. © 2021 Ivanovo State University of Chemistry and Technology. All rights reserved.

16.
Nevrologiya, Neiropsikhiatriya, Psikhosomatika ; 13(6):67-72, 2021.
Article in Russian | Scopus | ID: covidwho-1643945

ABSTRACT

The novel coronavirus infection pandemic prompted not only the development of vaccines, but also the study of the effectiveness of already known drugs with antiviral activity. These drugs include adamantanes. Objective: to assess possible mechanisms of antiviral action of amantadine and memantine. Patients and methods. The study included 75 patients with Parkinson's disease (PD): 49 (65.3%) women and 26 (34.7%) men. The age of the patients ranged from 37 to 88 years (mean age: 65±7 years). The duration of the disease varied from 1 to 25 years (mean 12±7 years). Among the monitored PD patients, 22 (29.3%) had a novel coronavirus infection. Of 22 patients with coronavirus infection, 8 (36.4%) patients received adamantanes (four - amantadine sulfate, three - amantadine hydrochloride, one - memantine) in the complex therapy of PD for at least 3 months. On average, the duration of adamantane administration was 8±5 months. Results and discussion. PD patients who received adamantanes were less likely to develop COVID-19 than those who did not take adamantanes (p<0.05). At the same time, there were no significant differences in gender, age, duration of the disease and concomitant pathology in the compared groups (p>0.05). Among patients who received adamantanes, the disease proceeded more easily, the number of cases of pneumonia was 3 times less (odds ratio 3;95% confidence interval 0.44-20.3). In this group, no lethal outcomes were recorded, however, due to the small sample of patients, the differences between the groups were not statistically significant (χ2=1.99;p>0.05). Conclusion. The results of a retrospective study showed that the use of amantadine and memantine in patients with PD may have an effect on reducing morbidity and mortality in the novel coronavirus infection. This is consistent with published clinical observations suggesting a possible protective effect of amantadine and memantine against coronavirus infection. © 2021 Ima-Press Publishing House. All rights reserved.

17.
Eksperimental'naya i Klinicheskaya Gastroenterologiya ; - (8):175-180, 2021.
Article in Russian | Scopus | ID: covidwho-1599956

ABSTRACT

The article presents a clinical case of the fatal Mallory-Weiss syndrome, which suddenly developed in an 86-year-old patient with a new coronavirus infection COVID-19, complicated by bilateral polysegmental pneumonia. The patient had no history of gastroesophageal reflux disease, gastric ulcer or duodenal ulcer. The level of D-dimer on admission was elevated, but the patient was prescribed a reduced dose of anticoagulants (heparin). Despite the initial positive dynamics of the condition, the patient had a wave-like course of COVID-19, followed by the development of Mallory-Weiss syndrome, extremely severe post-hemorrhagic anemia and multiple organ failure, which became the cause of death. © 2021 Global Media Tekhnologii. All Rights Reserved.

18.
40th Chinese Control Conference, CCC 2021 ; 2021-July:3357-3362, 2021.
Article in English | Scopus | ID: covidwho-1485675

ABSTRACT

Telemedicine is of growing importance for the increasing number of patients with population aging, lack of medical resources in the countryside, and special situation such as the COVID-19 pandemic. Gait impairment is a major motor symptom for patients suffering from neurological disorders such as Parkinson's disease (PD), and serves as an important indicator for early screening and diagnosis of the disease. Existing gait analysis methods typically require advanced equipment, trained professionals, and complex procedures. In this paper, we propose a method to classify the abnormal gait of patients suffering from Parkinson's disease and normal gait, solely with the 2D walking videos recorded by a common camera or a smartphone. A pose estimation algorithm is employed to extract the skeleton of the subjects from the videos. Based on the analysis of motor disturbances resulting from Parkinson's disease, specific gait features are defined and extracted, including step length, walking speed, arm swing magnitude, and velocity. Considering that the sample size of clinical data is limited in the early stage, classic classifiers are applied, including logistic regression (LR), support vector machine (SVM), and random forest (RF). The registered clinical study was conducted with 20 PD patients and 20 age-matched healthy controls. With the three classifiers, 87.5% (LR), 90.0% (SVM), and 92.5% (RF) of classification accuracy were achieved, respectively. Thus, video-based classification of abnormal gait promises a solution for remote screening and diagnosis of neurological diseases. © 2021 Technical Committee on Control Theory, Chinese Association of Automation.

19.
Vestn Oftalmol ; 137(5. Vyp. 2): 331-339, 2021.
Article in Russian | MEDLINE | ID: covidwho-1478751

ABSTRACT

The review presents data on damage to the organ of vision in patients recovered from the new coronavirus infection reflecting on the results obtained by various researchers from examining patients with varying severity of the disease, both during the active stage and after recovery. Possible ways of transmission of the infectious agent into the organ of vision were analyzed. The most common ocular manifestation of COVID-19 is conjunctivitis, while lesions of the retina and optic nerve were noted less often. The article also outlines the strategy for treatment and describes infection prevention measures for doctors and patients.


Subject(s)
COVID-19 , Conjunctivitis , Eye Diseases/virology , COVID-19/complications , Conjunctivitis/virology , Humans , Ophthalmology , SARS-CoV-2 , Post-Acute COVID-19 Syndrome
20.
5th International Joint Conference on Asia-Pacific Web and Web-Age Information Management, APWeb-WAIM 2021 ; 12858 LNCS:140-145, 2021.
Article in English | Scopus | ID: covidwho-1437168

ABSTRACT

Suicide ideation detection on social media is a challenging problem due to its implicitness. In this paper, we present an approach to detect suicide ideation on social media based on a BERT-LSTM model with Adversarial and Multi-task learning (BLAM). More specifically, BLAM combines BERT model with Bi-LSTM model to extract deeper and richer features. Furthermore, emotion classification is utilized as an auxiliary task to perform multi-task learning, which enriches the extracted features with emotion information that enhances the identification of suicide. In addition, BLAM generates adversarial noise by adversarial learning improving the generalization ability of the model. Extensive experiments conducted on our collected Suicide Ideation Detection (SID) dataset demonstrate the competitive superiority of BLAM compared with the state-of-the-art methods. © 2021, Springer Nature Switzerland AG.

SELECTION OF CITATIONS
SEARCH DETAIL